Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203831 | 0.88 | ALDH1A1 (0.68) | ALDH1A1LMNASLC6A2SLC6A4MAPT | |
| SCHEMBL3198850 | 0.85 | ALDH1A1 (0.50) | ALDH1A1LMNASLC6A2SLC6A4MAPT | |
| SCHEMBL9806982 | 0.84 | ALDH1A1 (0.57) | ALDH1A1LMNASLC6A2SLC6A4MAPT | |
| SCHEMBL12073359 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNASLC6A2SLC6A4MAPT | |
| SCHEMBL473339 | 0.81 | LMNA (0.64) | ALDH1A1LMNAMMP1MMP2MMP3 | |
| SCHEMBL17152923 | 0.81 | ALDH1A1 (0.70) | ALDH1A1LMNASLC6A2SLC6A4MAPT | |
| SCHEMBL9067644 | 0.79 | ALDH1A1 (0.50) | ALDH1A1LMNASLC6A2SLC6A4MAPT | |
| SCHEMBL22525574 | 0.79 | ALDH1A1 (0.62) | ALDH1A1LMNASLC6A2SLC6A4MAPT | |
| SCHEMBL24225014 | 0.78 | ALDH1A1 (0.50) | ALDH1A1LMNASLC6A2SLC6A4MAPT | |
| SCHEMBL3259969 | 0.78 | ALDH1A1 (0.37) | ALDH1A1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | ALDH1A1 1501/4885LMNA 133/4885SLC6A2 2699/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | ALDH1A1 3543/4885LMNA 277/4885SLC6A2 3292/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | ALDH1A1 1151/4885LMNA 105/4885SLC6A2 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.